Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
66. |
ECCT/23/12/01 | PEARL RSVt Vaccine Study Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL) |
Principal Investigator(s) 1. Prof Walter Jaoko 2. Dr. Lucas Thina Otieno 3. Prof. Kariuki Simon 4. Dr. Janet Nyawira Oyieko 5. Walter Otieno 6. Onono Dr. Marcianah 7. Dr. Lucas Thina Otieno 8. Prof. Kariuki Simon 9. Dr. Janet Nyawira Oyieko 10. Walter Otieno 11. Onono Dr. Marcianah Site(s) in Kenya 1. KAVI-Institute of Clinical Research, University of Nairobi (Nairobi City county) 2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) 3. Walter Reed Army Institute of Research -Kericho Site (Kericho county) 4. KEMRI CCR – Butere Clinical Research Centre (Kakamega county) 5. Siaya County Referral Hospital (SCRH (Siaya county) 6. Kenya Medical Research Institute Center for Microbiology Research (CMR (Kisumu county) 7. Kombewa Clinical Research Center, KEMRI, (Kisumu county) |
View |
67. |
ECCT/23/11/06 | MPZ-MAL-01 A Phase 2a, Multicenter, Open-label, Dose-finding, Dose Escalation Study of Meplazumab in Adult Patients Diagnosed with Uncomplicated Plasmodium falciparum Malaria |
Principal Investigator(s) 1. Bernhards Ogutu Site(s) in Kenya 1. AHERO CLINICAL TRIALS UNIT (Kisumu county) 2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) 3. Kenya Medical Research Institute(KEMRI):Siaya Clinical Research Annex (Siaya county) |
View |
68. |
ECCT/23/11/05 | Alma Study Feasibility clinical study of the Alma system in treating Primary Postpartum Hemorrhage - Alma Study |
Principal Investigator(s) 1. Omondi Ogutu Site(s) in Kenya Kenyatta National Hospital |
View |
69. |
ECCT/23/11/04 | AUB Study A phase 1, single-center, double-blind, randomized, placebo-controlled trial to assess the safety, tolerability and initial efficacy of AHC01 delivered via transcervical catheter in adult females (25-55 years), experiencing abnormal uterine bleeding and scheduled for a hysterectomy. |
Principal Investigator(s) 1. Dr Alice Kaaria Site(s) in Kenya Kenyatta National Hospital (KNH) |
View |
70. |
ECCT/23/11/02 | CROSSWALK Acute (A) A PHASE IB, RANDOMIZED, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF CROVALIMAB FOR THE MANAGEMENT OF ACUTE UNCOMPLICATED VASO‑OCCLUSIVE EPISODES (VOE) IN PATIENTS WITH SICKLE CELL DISEASE (SCD) |
Principal Investigator(s) 1. Fredrick Chite Asirwa Site(s) in Kenya 1. In this submission: International Cancer Institute (Uasin Gishu county) |
View |